Physician profile
Umal Azmat
NPI 1417260803
$4,149.39
in general payments reported to CMS, 2019-2025
32 companies · $1,734 in 2025
The $1,734 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,044 · 2024: $1,371 · 2025: $1,734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,149.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $557.27 | 2023-2025 | Mounjaro, Jardiance |
| Novo Nordisk INC | $384.12 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $345.66 | 2023-2025 | |
| Amgen INC. | $303.08 | 2023-2025 | Tepezza, Repatha, Evenity |
| Dexcom, INC. | $281.64 | 2023-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $278.09 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $243.07 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.14 | 2023-2025 | Jardiance |
| Abbott Laboratories | $159.43 | 2024-2025 | Freestyle Libre |
| Medtronic, INC. | $131.36 | 2023-2025 | Minimed 780g |
| Amneal Pharmaceuticals LLC | $125.94 | 2023-2025 | Unithroid |
| Madrigal Pharmaceuticals | $117.81 | 2025 | Rezdiffra |
| Radius Health, INC. | $101.45 | 2024-2025 | Tymlos |
| Recordati_rare_diseases_inc. | $95.36 | 2024-2025 | Isturisa |
| Abbvie INC. | $81.74 | 2024-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $69.24 | 2023-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Amphastar Pharmaceuticals, INC. | $68.95 | 2024-2025 | |
| Antares Pharma, INC. | $64.08 | 2024-2025 | Xyosted |
| Ascendis Pharma Endocrinology INC | $60.38 | 2025 | Yorvipath |
| Cequr Corporation | $59.55 | 2025 | Cequr Simplicity |
| Alexion Pharmaceuticals, INC. | $53.50 | 2023 | Strensiq |
| Sequel Med Tech, LLC | $51.75 | 2025 | Twiist |
| Esperion Therapeutics, INC. | $51.40 | 2024-2025 | Nexletol |
| Corcept Therapeutics | $51.31 | 2023-2025 | Korlym |
| Kyowa Kirin, INC. | $48.51 | 2024-2025 | Crysvita |
| Ascensia Diabetes Care US INC. | $47.15 | 2024-2025 | |
| Astellas Pharma US INC | $39.09 | 2025 | Veozah |
| Neurocrine Biosciences, INC. | $30.39 | 2025 | |
| Horizon Therapeutics Plc | $24.25 | 2023 | Tepezza |
| Renalytix Ai, INC. | $22.19 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Averitas Pharma INC. | $21.54 | 2023 | Qutenza |
| Glaxosmithkline, LLC. | $14.95 | 2025 | Arexvy, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Umal Azmat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.